Lara Sullivan - 07 Oct 2021 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Executive Officer, Director
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan
Issuer symbol
PYXS
Transactions as of
07 Oct 2021
Net transactions value
$0
Form type
4
Filing time
12 Oct 2021, 19:47:31 UTC
Next filing
04 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to buy) Award $0 +962,289 $0.000000 962,289 07 Oct 2021 Common Stock 962,289 $16.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Two-thirds of these stock options vest 25% on the first anniversary of the October 7, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, and one-third of these stock options vest in full on the fourth anniversary of the October 7, 2021 grant date, all subject to the reporting person's continued employment through the applicable vesting date.